SCHEMBL5861610

SCHEMBL5861610

CCOC(=O)C(Cc1ccccn1)(C(=O)OCC)c1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
ALDH1A1 P00352 3/20 0.40
HPGD P15428 3/20 0.40
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
FDPS P14324 1/20 0.39
RAB9A P51151 3/20 0.39
LMNA P02545 1/20 0.39
NPC1 O15118 2/20 0.38
GPR119 Q8TDV5 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CASP3 P42574 1/20 0.38
SENP8 Q96LD8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7780096 0.94 ALDH1A1 (0.41) POLBALDH1A1HPGDKMT2AKDM4E
SCHEMBL5861519 0.80 TRPM8 (0.47) ALDH1A1KMT2AKDM4EFDPSRAB9A
SCHEMBL5860443 0.79 L3MBTL1 (0.41) ALDH1A1HPGDKMT2AKDM4EFDPS
SCHEMBL5862781 0.78 ALDH1A1 (0.47) ALDH1A1KMT2AKDM4EFDPSRAB9A
SCHEMBL5140898 0.78 CYP1A2 (0.48) ALDH1A1KMT2AKDM4EFDPSRAB9A
SCHEMBL5861527 0.78 RAB9A (0.46) POLBALDH1A1KMT2AKDM4EFDPS
SCHEMBL5861419 0.77 MAPT (0.40) POLBALDH1A1KMT2AKDM4EFDPS
SCHEMBL7787285 0.77 TRPM8 (0.45) POLBALDH1A1KDM4EFDPSRAB9A
SCHEMBL7810409 0.76 ALDH1A1 (0.45) POLBALDH1A1KMT2AKDM4EFDPS
SCHEMBL7780059 0.75 RAB9A (0.43) ALDH1A1KMT2AKDM4EFDPSRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7012146-B2 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2006-03-14 US claimed
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US claimed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP claimed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO claimed
US-7012146-B2 Ion channel modulating agents POSEIDON PHARMACEUTICALS A/S (DK) 2006-03-14 US disclosed
US-20020169203-A1 Ion channel modulating agents NEUROSEARCH A/S (DK) 2002-11-14 US disclosed
EP-1140784-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2001-10-10 EP disclosed
WO-2000037422-A2 ION CHANNEL MODULATING AGENTS NEUROSEARCH A/S (DK) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169203-A1 Ion channel modulating agents KCNN3, KCNN1, KCNN2 POLB 4824/4885ALDH1A1 4482/4885HPGD 1762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.